EXAS
NASDAQ · Biotechnology
Exact Sciences Corp
$104.91
+0.99 (+0.95%)
Financial Highlights (FY 2026)
Revenue
2.86B
Net Income
-1,066,070,480
Gross Margin
69.5%
Profit Margin
-37.3%
Rev Growth
+16.0%
D/E Ratio
1.08
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.5% | 69.5% | 65.2% | 65.2% |
| Operating Margin | -37.6% | -33.9% | -19.8% | -16.2% |
| Profit Margin | -37.3% | -35.4% | -15.6% | -20.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.86B | 2.46B | 5.75B | 5.27B |
| Gross Profit | 1.99B | 1.71B | 3.75B | 3.43B |
| Operating Income | -1,076,003,609 | -834,758,424 | -1,140,404,105 | -853,966,878 |
| Net Income | -1,066,070,480 | -827,052,350 | -895,146,132 | -1,079,598,147 |
| Gross Margin | 69.5% | 69.5% | 65.2% | 65.2% |
| Operating Margin | -37.6% | -33.9% | -19.8% | -16.2% |
| Profit Margin | -37.3% | -35.4% | -15.6% | -20.5% |
| Rev Growth | +16.0% | +16.0% | -4.7% | +13.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.12B | 5.12B | 1.25B | 1.44B |
| Total Equity | 4.74B | 4.74B | 14.33B | 13.57B |
| D/E Ratio | 1.08 | 1.08 | 0.09 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,064,505,424 | -871,718,087 | -1,423,315,581 | -1,251,341,027 |
| Free Cash Flow | — | — | -873,819,141 | -1,059,999,929 |